Adipose tissue metabolism and cardiometabolic health in obesity:effects of pharmacological and lifestyle interventions by Stinkens, Rudi Michel Elisabeth
  
 
Adipose tissue metabolism and cardiometabolic
health in obesity
Citation for published version (APA):
Stinkens, R. M. E. (2017). Adipose tissue metabolism and cardiometabolic health in obesity: effects of
pharmacological and lifestyle interventions. Maastricht: Maastricht University.
https://doi.org/10.26481/dis.20171005rs
Document status and date:
Published: 01/01/2017
DOI:
10.26481/dis.20171005rs
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
Chapter 9 
258 
 
 
 
 
 
 
 
 
 
VALORIZATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9 
259 
SOCIAL RELEVANCE 
The worldwide prevalence of obesity has increased enormously over the last 
decades and numbers are still increasing every year. According to the World 
Health Organization, 13% of the world’s adult population (11% of men and 15% of 
women) was obese in 2014, while in the same year, obesity affected around 18,5% 
of men and 19% of woman in The Netherlands [1]. If post-2000 trends continue, 
this global prevalence of obesity is suggested to reach 18% in men and 21% in 
women by 2025. Obesity is associated with an increased risk of developing chronic 
diseases, including insulin resistance [2], type 2 diabetes [3], cardiovascular 
diseases [4] and certain types of cancer [5, 6]. To reduce these obesity related 
comorbidities, nowadays, millions of people are in need of medication, such as 
glucose-, cholesterol- and/or blood pressure lowering medication, and surgical 
treatments such as gastric bypass or cardiovascular surgery. Since obesity is a 
major public health issue and one of the most important risk factors for the 
development of metabolic diseases, it is clear that the increasing obesity 
prevalence has major socioeconomic consequences [7]. National and international 
guidelines recommend changes in modifiable lifestyle characteristics, such as diet 
and physical activity for both prevention and management of metabolic diseases 
[8]. While weight loss has been shown to be effective in reducing disease risk, 
implementation of the recommended lifestyle in the long-term is often hard to 
maintain by the majority of people. Therefore, to reduce the incidence of obesity 
and thereby partly improving global health, it is important to obtain better insights in 
the development and treatment of obesity and related metabolic diseases and to 
implement new treatment strategies. The results described in this thesis contribute 
to a better understanding of the role of adipose tissue metabolism in 
cardiometabolic health and obesity, and provide leads for possible treatment 
strategies to reduce or prevent obesity and cardiometabolic complications. 
 
 
TARGET GROUPS 
 
Scientific community 
The results described in this thesis have and will become available to the scientific 
community via publication of scientific articles in international peer-reviewed 
journals. Additionally, results have been presented at (inter)national conferences to 
scientists as well as physicians, healthcare professionals and dieticians, working in 
the fields of obesity, diabetes and metabolism. 
 
Industry 
A part of this thesis was accomplished by the close collaboration between 
academia and industry and research outcomes are of valuable information to the 
academic community and both the nutritional and the pharmaceutical industry. The 
industrial partners can translate the research outcomes to develop improved or 
novel treatment strategies or products that help to prevent or reduce the 
prevalence of obesity and obesity-related complications. More specific, the 
nutritional industry can translate the results from chapter 2 in defining new 
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nutritional targets. The pharmacological industry can use the results from this 
thesis to develop and/or implement new or improved pharmacological therapies or 
to expand the rationale for prescribing certain cardiovascular drugs in metabolically 
compromised conditions, since in our studies combination therapy with 
sacubitril/valsartan was shown to improve both cardiovascular and metabolic risk 
factors. 
 
Health care professionals 
Healthcare professionals (e.g. dieticians, physiotherapists and physicians) play an 
important role in stimulating a healthy lifestyle among patients and people at 
increased risk of developing obesity and related complications. On the other hand, 
physicians prescribe drugs to reverse for example cardiovascular risk (e.g. 
hypertension) or to improve glucose metabolism and insulin sensitivity. Although 
the results from this thesis do no provide direct guidelines for healthcare, they 
provide better insight in metabolic parameters that can be targeted through certain 
interventions, applied by physicians and other healthcare professionals. 
Furthermore, this thesis might provide an indication for more targeted prevention 
programs in high risk groups of the population (i.e. people with both cardiovascular 
and metabolic risk factors) and it gives more insight in the mechanism of action of a 
cardiovascular drug (i.e. sacubitril/valsartan) that also has effects on insulin 
sensitivity and which therefore may alter the rationale for prescription. 
 
 
ACTIVITIES AND PRODUCTS 
In this thesis, we have put forward fatty acid metabolism-related pathways in 
several metabolically active organs that can be targeted by dietary interventions, 
thereby improving whole-body glucose metabolism and insulin sensitivity. The 
results from the nutritional review can potentially lead to novel functional foods or 
food supplements (e.g. pre- and probiotics, polyphenols, plant sterols, improved 
dietary fat quality). However, before these novel products will become available on 
the market, more scientific research is necessary to confirm mechanisms, safety 
and health benefits in individuals at increased risk of developing cardiometabolic 
diseases. 
 
The results from the pharmacological intervention with sacubitril/valsartan, which 
has recently been approved by the U.S. Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) for the treatment of heart failure [9], 
showed that the combination therapy has a positive effect on cardiovascular and 
metabolic risk factors. We showed that treatment with sacubitril/valsartan, as 
compared to the metabolically neutral calcium antagonist amlodipine, improved 
peripheral insulin sensitivity in obese hypertensive patients. This knowledge will be 
immediately used by the pharmaceutical industry. Moreover, sacubitril/valsartan 
may be a promising alternative for the treatment of hypertension in patients who 
are at increased risk for developing chronic metabolic diseases (e.g. hypertensive 
individuals with impaired glucose metabolism). 
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The exercise training intervention studies showed that exercise training beneficially 
affects body composition and physical fitness and is effective to improve obesity-
related disturbances like whole-body insulin resistance. Although 12 weeks of 
exercise training induced a slight but significant reduction in fat mass, no significant 
changes in abdominal subcutaneous adipocyte morphology, adipose tissue 
function, and abdominal subcutaneous adipose tissue lipolysis were observed in 
obese subjects, irrespective of their baseline metabolic status. Furthermore, we 
showed that 12 weeks of exercise training did not improve disturbances in 
subcutaneous adipose tissue lipolysis in obese insulin resistant individuals. It 
seems that a more pronounced decrease in adipose tissue mass is needed to 
induce significant changes in adipose tissue metabolism. Currently, it remains to be 
established which exercise training duration and modality is most optimal to induce 
beneficial effects in abdominal subcutaneous adipose tissue. 
 
 
INNOVATION & IMPLEMENTATION 
All results described in this thesis are novel findings and have, partly, been 
performed at the Department of Human Biology and Movement Sciences of 
Maastricht University Medical Center+ and in close collaboration with other 
universities and industrial partners within The Netherlands and Europe, using state-
of-the-art methodologies for both in vivo and ex vivo analyses. 
 
An attractive approach, as described in this thesis, is the application of combination 
therapy, which simultaneously targets more than one biological pathway or 
mechanism and therefore may be more effective in reducing disease progression 
because of additional and/or synergistic effects as compared to monotherapies [10] 
[11]. With respect to the pharmacological treatment with the combination drug, 
sacubitril/valsartan, this thesis is the first to describe the beneficial metabolic 
effects (i.e. improved insulin sensitivity) in obese hypertensive patients. However, 
to implement these results in treatment strategies for the hypertensive population, 
more research is necessary to unravel the underlying mechanisms in different 
metabolic tissues (e.g. skeletal muscle) and long-term health outcomes of therapy 
with the combinational drug sacubitril/valsartan. 
 
The innovative aspect of the exercise training interventions, was the investigation 
of exercise training-induced effects on abdominal subcutaneous adipose tissue, 
since these studies have mainly been performed in rodents whereas human 
studies are scarce. Our results contribute to the knowledge and provide better 
insight in exercise training-mediated metabolic changes in abdominal 
subcutaneous adipose tissue. 
Furthermore, metabolic phenotyping at baseline makes it possible to stratify 
subjects into different subgroups and may improve the effectiveness of a particular 
intervention in a specific subgroup of the population [12]. However, in this thesis we 
did not find clear evidence that metabolic phenotype at baseline affected exercise 
training-induced study outcomes. Therefore, before extrapolating our findings to a 
larger population, more research is necessary in larger study populations following 
different intervention strategies (e.g. nutritional, pharmacological as well as 
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prolonged exercise training interventions). Studies including more detailed 
metabolic phenotyping such as tissue-specific profiling are needed not only to 
identify individuals or subgroups at increased risk of developing metabolic 
diseases, but also to design optimized prevention and treatment strategies for 
specific subgroups of the population. These promising strategies will be further 
investigated by the current project team by performing human intervention trials 
including in vivo and laboratory analyses, performed via state-of-the-art research 
methodologies. 
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